Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Commun Med (Lond) ; 4(1): 58, 2024 Mar 26.
Article in English | MEDLINE | ID: mdl-38532017

ABSTRACT

BACKGROUND: Natural cytokines are poorly suited as therapeutics for systemic administration due to suboptimal pharmacological and pharmacokinetic (PK) properties. Recombinant human interleukin-2 (rhIL-2) has shown promise for treatment of autoimmune (AI) disorders yet exhibits short systemic half-life and opposing immune responses that negate an appropriate therapeutic index. METHODS: A semi-synthetic microbial technology platform was used to engineer a site-specifically pegylated form of rhIL-2 with enhanced PK, specificity for induction of immune-suppressive regulatory CD4 + T cells (Tregs), and reduced stimulation of off-target effector T and NK cells. A library of rhIL-2 molecules was constructed with single site-specific, biorthogonal chemistry-compatible non-canonical amino acids installed near the interface where IL-2 engages its cognate receptor ßγ (IL-2Rßγ) signaling complex. Biorthogonal site-specific pegylation and functional screening identified variants that retained engagement of the IL-2Rα chain with attenuated potency at the IL-2Rßγ complex. RESULTS: Phenotypic screening in mouse identifies SAR444336 (SAR'336; formerly known as THOR-809), rhIL-2 pegylated at H16, as a potential development candidate that specifically expands peripheral CD4+ Tregs with upregulation of markers that correlate with their suppressive function including FoxP3, ICOS and Helios, yet minimally expands CD8 + T or NK cells. In non-human primate, administration of SAR'336 also induces dose-dependent expansion of Tregs and upregulated suppressive markers without significant expansion of CD8 + T or NK cells. SAR'336 administration reduces inflammation in a delayed-type hypersensitivity mouse model, potently suppressing CD4+ and CD8 + T cell proliferation. CONCLUSION: SAR'336 is a specific Treg activator, supporting its further development for the treatment of AI diseases.


Interleukin-2 (IL-2) is a protein that functions as a master regulator of immune responses. A key function of IL-2 is the stimulation of immune-regulatory cells that suppress autoimmune disease, which occurs when the body's immune system mistakenly attacks healthy tissues. However, therapeutic use of IL-2 is limited by its short duration of action and incomplete selectivity for immune-suppressive cells over off-target immune-stimulatory cells. We employ a platform that we have previously developed, which is a bacterial organism with an expanded DNA code, to identify a new version of IL-2, SAR444336 (SAR'336), with an extended duration of activity and increased selectivity for immune-suppressive cells. In mice and monkeys, SAR'336 was a specific activator of immune suppression, with minimal effect on immune cells that stimulate autoimmunity. Our results support further development of SAR'336 for treatment of autoimmune disorders.

2.
Nat Commun ; 12(1): 4785, 2021 08 09.
Article in English | MEDLINE | ID: mdl-34373459

ABSTRACT

The implementation of applied engineering principles to create synthetic biological systems promises to revolutionize medicine, but application of fundamentally redesigned organisms has thus far not impacted practical drug development. Here we utilize an engineered microbial organism with a six-letter semi-synthetic DNA code to generate a library of site-specific, click chemistry compatible amino acid substitutions in the human cytokine IL-2. Targeted covalent modification of IL-2 variants with PEG polymers and screening identifies compounds with distinct IL-2 receptor specificities and improved pharmacological properties. One variant, termed THOR-707, selectively engages the IL-2 receptor beta/gamma complex without engagement of the IL-2 receptor alpha. In mice, administration of THOR-707 results in large-scale activation and amplification of CD8+ T cells and NK cells, without Treg expansion characteristic of IL-2. In syngeneic B16-F10 tumor-bearing mice, THOR-707 enhances drug accumulation in the tumor tissue, stimulates tumor-infiltrating CD8+ T and NK cells, and leads to a dose-dependent reduction of tumor growth. These results support further characterization of the immune modulatory, anti-tumor properties of THOR-707 and represent a fundamental advance in the application of synthetic biology to medicine, leveraging engineered semi-synthetic organisms as cellular factories to facilitate discovery and production of differentiated classes of chemically modified biologics.


Subject(s)
Antineoplastic Agents/therapeutic use , Interleukin-2/chemistry , Interleukin-2/metabolism , Interleukin-2/pharmacology , Animals , CD8-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/immunology , Drug Discovery , Genetic Engineering , Humans , Interleukin-2/genetics , Interleukin-2 Receptor alpha Subunit , Killer Cells, Natural/drug effects , Killer Cells, Natural/immunology , Lymphocytes/drug effects , Mice , Synthetic Biology
4.
PLoS One ; 11(5): e0154616, 2016.
Article in English | MEDLINE | ID: mdl-27171010

ABSTRACT

A proof-of-concept study evaluating the potential of Streptococcus pneumoniae Pneumococcal Surface Protein A (PspA) as a passive immunization target was conducted. We describe the generation and isolation of several broadly reactive mouse anti-PspA monoclonal antibodies (mAbs). MAb 140H1 displayed (i) 98% strain coverage, (ii) activity in complement deposition and opsonophagocytic killing (OPK) assays, which are thought to predict the in vivo efficacy of anti-pneumococcal mAbs, (iii) efficacy in mouse sepsis models both alone and in combination with standard-of-care antibiotics, and (iv) therapeutic activity in a mouse pneumonia model. Moreover, we demonstrate that antibody engineering can significantly enhance anti-PspA mAb effector function. We believe that PspA has promising potential as a target for the therapy of invasive pneumococcal disease by mAbs, which could be used alone or in conjunction with standard-of-care antibiotics.


Subject(s)
Antibodies, Monoclonal/immunology , Bacterial Proteins/immunology , Streptococcus pneumoniae/immunology , Animals , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/therapeutic use , Complement C3/metabolism , Disease Models, Animal , Epitope Mapping , Female , Humans , Immunoglobulin G/blood , Lung Diseases/immunology , Lung Diseases/microbiology , Mice, Inbred BALB C , Opsonin Proteins/metabolism , Phagocytes/metabolism , Phagocytosis , Pneumococcal Infections/drug therapy , Pneumococcal Infections/immunology , Pneumococcal Infections/microbiology , Protein Binding , Sepsis/drug therapy , Sepsis/immunology , Sepsis/microbiology , Treatment Outcome
5.
J Virol ; 87(3): 1569-85, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23152530

ABSTRACT

The extracellular virion form (EV) of vaccinia virus (VACV) is essential for viral pathogenesis and is difficult to neutralize with antibodies. Why this is the case and how the smallpox vaccine overcomes this challenge remain incompletely understood. We previously showed that high concentrations of anti-B5 antibodies are insufficient to directly neutralize EV (M. R. Benhnia, et al., J. Virol. 83:1201-1215, 2009). This allowed for at least two possible interpretations: covering the EV surface is insufficient for neutralization, or there are insufficient copies of B5 to allow anti-B5 IgG to cover the whole surface of EV and another viral receptor protein remains active. We endeavored to test these possibilities, focusing on the antibody responses elicited by immunization against smallpox. We tested whether human monoclonal antibodies (MAbs) against the three major EV antigens, B5, A33, and A56, could individually or together neutralize EV. While anti-B5 or anti-A33 (but not anti-A56) MAbs of appropriate isotypes were capable of neutralizing EV in the presence of complement, a mixture of anti-B5, anti-A33, and anti-A56 MAbs was incapable of directly neutralizing EV, even at high concentrations. This remained true when neutralizing the IHD-J strain, which lacks a functional version of the fourth and final known EV surface protein, A34. These immunological data are consistent with the possibility that viral proteins may not be the active component of the EV surface for target cell binding and infectivity. We conclude that the protection afforded by the smallpox vaccine anti-EV response is predominantly mediated not by direct neutralization but by isotype-dependent effector functions, such as complement recruitment for antibodies targeting B5 and A33.


Subject(s)
Antibodies, Neutralizing/immunology , Antibodies, Viral/immunology , Smallpox Vaccine/immunology , Vaccinia virus/immunology , Virion/immunology , Antibodies, Monoclonal/immunology , Antigens, Viral/immunology , Complement System Proteins/immunology , Humans , Neutralization Tests
6.
PLoS One ; 7(11): e48706, 2012.
Article in English | MEDLINE | ID: mdl-23133652

ABSTRACT

Smallpox (variola virus) is a bioweapon concern. Monkeypox is a growing zoonotic poxvirus threat. These problems have resulted in extensive efforts to develop potential therapeutics that can prevent or treat potentially lethal poxvirus infections in humans. Monoclonal antibodies (mAbs) against smallpox are a conservative approach to this problem, as the licensed human smallpox vaccine (vaccinia virus, VACV) primarily works on the basis of protective antibody responses against smallpox. Fully human mAbs (hmAbs) against vaccinia H3 (H3L) and B5 (B5R), targeting both the mature virion (MV) and extracellular enveloped virion (EV) forms, have been developed as potential therapeutics for use in humans. Post-exposure prophylaxis was assessed in both murine and rabbit animal models. Therapeutic efficacy of the mAbs was assessed in three good laboratory practices (GLP) studies examining severe combined immunodeficiency mice (SCID) given a lethal VACV infection. Pre-exposure combination hmAb therapy provided significantly better protection against disease and death than either single hmAb or vaccinia immune globulin (VIG). Post-exposure combination mAb therapy provided significant protection against disease and death, and appeared to fully cure the VACV infection in ≥50% of SCID mice. Therapeutic efficacy was then assessed in two rabbit studies examining post-exposure hmAb prophylaxis against rabbitpox (RPXV). In the first study, rabbits were infected with RPVX and then provided hmAbs at 48 hrs post-infection, or 1 hr and 72 hrs post-infection. Rabbits in both groups receiving hmAbs were 100% protected from death. In the second rabbitpox study, 100% of animal treated with combination hmAb therapy and 100% of animals treated with anti-B5 hmAb were protected. These findings suggest that combination hmAb treatment may be effective at controlling smallpox disease in immunocompetent or immunodeficient humans.


Subject(s)
Poxviridae Infections/diagnosis , Poxviridae Infections/immunology , Animals , Antibodies, Monoclonal/chemistry , Antibodies, Monoclonal/physiology , Blood/metabolism , Body Weight , Disease Models, Animal , Female , HeLa Cells , Humans , Liver/metabolism , Mice , Mice, SCID , Neutralization Tests , Rabbits , Spleen/metabolism , Time Factors , Vaccinia/immunology , Vaccinia/prevention & control , Vaccinia virus/immunology
7.
Antivir Ther ; 16(1): 67-75, 2011.
Article in English | MEDLINE | ID: mdl-21311110

ABSTRACT

BACKGROUND: Eczema vaccinatum is the most common severe pathology associated with smallpox vaccination (vaccinia virus), occurring at high rates among individuals with a previous history of atopic dermatitis (atopic eczema). METHODS: Monoclonal antibodies capable of neutralizing vaccinia virus, anti-H3 and anti-B5, were developed as a potential therapy for treatment of human eczema vaccinatum. RESULTS: Using a small animal model of eczema vaccinatum, we demonstrated that both murine and fully human monoclonal antibodies effectively limited eczema vaccinatum disease, foreshortening both the disease kinetics and the severity of the erosive viral skin lesions. CONCLUSIONS: These neutralizing antibodies would likely be effective at reducing or eliminating clinical disease in people with eczema vaccinatum or other severe side effects of the smallpox vaccine.


Subject(s)
Antibodies, Monoclonal, Murine-Derived/administration & dosage , Antibodies, Neutralizing/administration & dosage , Kaposi Varicelliform Eruption/immunology , Kaposi Varicelliform Eruption/prevention & control , Protective Agents/administration & dosage , Smallpox Vaccine/adverse effects , Vaccination/adverse effects , Animals , Antibodies, Monoclonal, Murine-Derived/immunology , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Antibodies, Neutralizing/immunology , Antibodies, Neutralizing/therapeutic use , Dermatitis, Atopic/complications , Dermatitis, Atopic/immunology , Disease Models, Animal , Humans , Kaposi Varicelliform Eruption/etiology , Kaposi Varicelliform Eruption/virology , Mice , Mice, Inbred Strains , Protective Agents/therapeutic use , Smallpox/immunology , Smallpox/prevention & control , Smallpox Vaccine/administration & dosage , Vaccinia virus/immunology , Vaccinia virus/pathogenicity
8.
Antivir Ther ; 15(4): 661-75, 2010.
Article in English | MEDLINE | ID: mdl-20587859

ABSTRACT

BACKGROUND: Treatment of rare severe side effects of vaccinia virus (VACV) immunization in humans is currently very challenging. VACV possesses two immunologically distinct virion forms in vivo - intracellular mature virion (MV, IMV) and extracellular virion (EV, EEV). METHODS: Antibody-mediated therapeutic efficacy was determined against VACV infection in a small animal model of progressive vaccinia. The model consisted of severe combined immunodeficiency mice infected with VACV New York City Board of Health vaccine strain and treated with monoclonal antibodies (mAbs). RESULTS: Here, we show that combination therapy with two fully human mAbs against an immunodominant MV antigen, H3 (H3L), and an EV antigen, B5 (B5R), provides significantly better protection against disease and death than either single human monoclonal or human vaccinia immune globulin, the currently licensed therapeutic for side effects of smallpox vaccination. CONCLUSIONS: The preclinical studies validate that this combination of mAbs against H3 and B5 is a promising approach as a poxvirus infection treatment for use in humans.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Carrier Proteins/immunology , Vaccinia virus/immunology , Vaccinia/drug therapy , Viral Envelope Proteins/immunology , Viral Matrix Proteins/immunology , Animals , Antibodies, Monoclonal/administration & dosage , Antibodies, Viral/administration & dosage , Antibodies, Viral/therapeutic use , Chlorocebus aethiops , Disease Models, Animal , Drug Therapy, Combination , Humans , Mice , Mice, Inbred BALB C , Mice, SCID , Neutralization Tests , Treatment Outcome , Vaccinia/immunology , Vero Cells
9.
J Virol ; 83(23): 12355-67, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19793826

ABSTRACT

Antibodies against the extracellular virion (EV or EEV) form of vaccinia virus are an important component of protective immunity in animal models and likely contribute to the protection of immunized humans against poxviruses. Using fully human monoclonal antibodies (MAbs), we now have shown that the protective attributes of the human anti-B5 antibody response to the smallpox vaccine (vaccinia virus) are heavily dependent on effector functions. By switching Fc domains of a single MAb, we have definitively shown that neutralization in vitro--and protection in vivo in a mouse model--by the human anti-B5 immunoglobulin G MAbs is isotype dependent, thereby demonstrating that efficient protection by these antibodies is not simply dependent on binding an appropriate vaccinia virion antigen with high affinity but in fact requires antibody effector function. The complement components C3 and C1q, but not C5, were required for neutralization. We also have demonstrated that human MAbs against B5 can potently direct complement-dependent cytotoxicity of vaccinia virus-infected cells. Each of these results was then extended to the polyclonal human antibody response to the smallpox vaccine. A model is proposed to explain the mechanism of EV neutralization. Altogether these findings enhance our understanding of the central protective activities of smallpox vaccine-elicited antibodies in immunized humans.


Subject(s)
Antibodies, Monoclonal/immunology , Antibodies, Viral/immunology , Immunoglobulin Isotypes/immunology , Smallpox/prevention & control , Vaccinia virus/immunology , Viral Matrix Proteins/immunology , Animals , Body Weight , Complement C1q/immunology , Complement C3/immunology , Female , Humans , Mice , Mice, Inbred BALB C , Models, Biological , Neutralization Tests , Survival Analysis
10.
J Virol ; 83(3): 1201-15, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19019965

ABSTRACT

Antibody neutralization is an important component of protective immunity against vaccinia virus (VACV). Two distinct virion forms, mature virion and enveloped virion (MV and EV, respectively), possess separate functions and nonoverlapping immunological properties. In this study we examined the mechanics of EV neutralization, focusing on EV protein B5 (also called B5R). We show that neutralization of EV is predominantly complement dependent. From a panel of high-affinity anti-B5 monoclonal antibodies (MAbs), the only potent neutralizer in vitro (90% at 535 ng/ml) was an immunoglobulin G2a (IgG2a), and neutralization was complement mediated. This MAb was the most protective in vivo against lethal intranasal VACV challenge. Further studies demonstrated that in vivo depletion of complement caused a >50% loss of anti-B5 IgG2a protection, directly establishing the importance of complement for protection against the EV form. However, the mechanism of protection is not sterilizing immunity via elimination of the inoculum as the viral inoculum consisted of a purified MV form. The prevention of illness in vivo indicated rapid control of infection. We further demonstrate that antibody-mediated killing of VACV-infected cells expressing surface B5 is a second protective mechanism provided by complement-fixing anti-B5 IgG. Cell killing was very efficient, and this effector function was highly isotype specific. These results indicate that anti-B5 antibody-directed cell lysis via complement is a powerful mechanism for clearance of infected cells, keeping poxvirus-infected cells from being invisible to humoral immune responses. These findings highlight the importance of multiple mechanisms of antibody-mediated protection against VACV and point to key immunobiological differences between MVs and EVs that impact the outcome of infection.


Subject(s)
Complement System Proteins/physiology , Vaccinia virus/immunology , Virion/immunology , Animals , Antibodies, Monoclonal/genetics , Antibodies, Monoclonal/immunology , Chlorocebus aethiops , Enzyme-Linked Immunosorbent Assay , Female , HeLa Cells , Humans , Mice , Mice, Inbred BALB C , Neutralization Tests , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Vero Cells
11.
Antiviral Res ; 80(2): 168-77, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18598723

ABSTRACT

Influenza is one of the most prevalent viral diseases in humans. For some high-risk human populations, including the infant, the elderly, and the immunocompromised, who may not benefit from active immunization, passive immunotherapy with antibodies reactive with all influenza A strains may be an alternative. In this study, we characterized several fully human monoclonal antibodies (MAb) reactive with M2e, which were generated from transchromosomic mice engineered to produce fully human antibodies following immunization with a consensus-sequence M2e peptide. The MAbs showed strong binding to M2e peptide and to virus infected MDCK cells. One MAb recognizing the highly conserved N-terminal portion of consensus M2e displayed high binding to the majority of M2e variants from natural viral isolates, including highly pathogenic avian strains, which were recently reported to infect humans. Passive immunotherapy with this MAb in mice resulted in significant reduction in virus replication in the lung and protection from lethal infection when administered either prophylactically or therapeutically. These results suggest the potential of the anti-M2e human MAb with broad binding spectrum as a universal passive immunotherapeutic agent to infection by influenza A virus.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Immunization, Passive , Influenza A virus/immunology , Influenza, Human/prevention & control , Viral Matrix Proteins/immunology , Amino Acid Sequence , Animals , Antibodies, Monoclonal/immunology , Antibodies, Viral/administration & dosage , Antibody Specificity , Cell Line , Dogs , Female , Humans , Influenza, Human/immunology , Influenza, Human/therapy , Mice , Mice, Inbred C57BL , Mice, Transgenic , Molecular Sequence Data
12.
Nat Struct Biol ; 10(1): 13-8, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12459720

ABSTRACT

Clostridial botulinum neurotoxins (BoNTs) abort the process of neurotransmitter release at presynaptic motor nerve terminals, causing muscle paralysis. An enigmatic step in the intoxication process is the mechanism by which the neurotoxin heavy chain (HC) forms the conduit for the translocation of the light chain (LC) protease across the endosomal membrane into the cytosol, its site of action. Here we investigate the mechanism of LC translocation by using the combined detection of channel currents and substrate proteolysis, the two hallmark activities of BoNT. Our data are consistent with the translocation of the LC through the HC channel and show that the LC protease activity is retrieved in the trans compartment after translocation. We propose that the BoNT HC-LC complex embedded in the membrane is a transmembrane chaperone, a dynamic structural device that prevents aggregation and achieves translocation of the LC. In this regard, the complex is similar to the protein conducting/translocating channels of the endoplasmic reticulum, mitochondria and chloroplasts.


Subject(s)
Botulinum Toxins/metabolism , Intracellular Membranes/metabolism , Neurotoxins/metabolism , Animals , Botulinum Toxins/chemistry , Cell Membrane/metabolism , Circular Dichroism , Cytoplasm/metabolism , Endoplasmic Reticulum/metabolism , Endosomes/metabolism , Humans , Ion Channels/physiology , Neurotoxins/chemistry , Peptide Hydrolases/metabolism , Protein Folding , Protein Transport/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...